Syncope Clinical Trial
Official title:
Diagnostic Yield of an Ambulatory Patch Monitor in Emergency Department Syncope Patients Unexplained After Emergency Department Evaluation: A Pilot Study (PATCH-ED)
Syncope is a common Emergency Department (ED) presentation but the underlying diagnosis is
not apparent in 60% of patients after assessment and serious adverse event rate is 7% at one
month with most having acute cardiovascular events, also more likely to be unexplained after
ED assessment. Many cardiovascular events are due to arrhythmia, difficult for clinicians to
diagnose, as examination and Electrocardiogram (ECG) findings may both be normal and symptoms
have resolved by the time the patient gets to the ED. Currently establishing a cardiac
arrhythmia as the cause of syncope rests on correlating the arrhythmia with symptoms using
monitoring devices such as Holter but these all have significant drawbacks. The clinical
challenge in the ED is therefore to identify the moderate and high-risk patients and refer
them for further investigation and monitoring if appropriate. The logistics of arranging
follow up within a timely period of the patient's ED visit is often problematic for a variety
of reasons including availability of timely specialty outpatient appointments, a lack of
consensus of the specialty to whom the syncope patient should be referred (cardiology,
medicine, neurology, general practice) and availability of Holter and other monitoring
devices. For this reason most high and medium risk patients are admitted to hospital.
Previous syncope clinical decision rules have not been well adopted due to their lack of
sensitivity and specificity probably due to the varied and heterogeneous nature of
potentially serious causes. However, the majority of patients with syncope have no serious
underlying pathology and do not require hospitalisation. Rather than continued attempts at
risk stratification of outcome based on presentation, more research is required into how we
can better improve diagnosis and therefore treatment in order to provide improved patient
benefit. We believe that ambulatory patch monitoring will allow better and earlier arrhythmia
detection and plan to assess the ability of a 14-day ambulatory patch to detect serious
arrhythmic outcomes at 90 days.
There are around 650,000 ED syncope presentations a year in the United Kingdom (UK). Serious
underlying conditions can present with syncope and one-month serious adverse outcome is
around 7% with 50% being cardiovascular. The treating ED clinician is not always able to rule
out serious pathology as the patient is commonly fully recovered on arrival in the ED,
despite the underlying cause being potentially life threatening should it recur again. Whilst
most patients do not have a serious underlying cause and therefore do not require
hospitalisation, the concern of the ED clinician about missing a serious underlying cause
(especially cardiovascular ones) means that 50% of syncope patients are admitted to hospital.
Despite research identifying high-risk demographic, historical and examination variables,
clinical decision rules have not been well adopted due to their lack of sensitivity and
specificity probably due to the varied and heterogeneous nature of potentially serious
causes. Rather than continued attempts at risk stratification of outcome based on
presentation, more research is required into how we can better improve diagnosis and
therefore treatment in order to provide improved patient benefit.
Cardiovascular causes of syncope fall into two main categories, arrhythmia (e.g. ventricular
tachycardia (VT), 2nd degree Mobitz II, 3rd degree atrioventricular block or symptomatic
bradycardia) and structural (e.g. aortic stenosis). It is arrhythmia that is most difficult
for the ED clinician to diagnose in the ED as examination and presenting Electrocardiogram
ECG may both be normal. It is for this reason that arrhythmia makes up a large number of
subsequent serious outcomes in syncope patients whose syncopal cause is unexplained after ED
assessment.
The current main method for establishing a cardiac arrhythmia as the cause of syncope rests
on the correlation of the arrhythmia with symptoms (which will have resolved by the time the
patient gets to the ED). The clinical challenge in the ED is therefore to identify the
moderate and high-risk patients and refer them for further investigation and monitoring if
appropriate. The logistics of arranging follow up within a timely period of the patient's ED
visit is often problematic for a variety of reasons including availability of timely
specialty outpatient appointments, a lack of consensus of the specialty to whom the syncope
patient should be referred (cardiology, medicine, neurology, general practice) and
availability of Holter and other monitoring devices. For this reason most high and medium
risk patients are admitted to hospital.
The investigation of cardiac arrhythmias is usually initiated with the Holter monitor which
uses a continuous recording over a 24 or 48-hour period. The Holter allows detection of
baseline rhythm, arrhythmia and conduction abnormalities. Holters however are bulky and
inconvenient for the patient to wear, the transmission of data is not patient dependent and
non-compliance with both device use and maintaining a written symptom log, limits its
diagnostic utility. The lack of extended monitoring reduces diagnostic yield to typically
less than 20%. Bass reported a diagnostic yield of 15% with 24-hour Holter monitoring that
did not increase even if the device was applied for 72 hours.
For these reasons, the use of Holter monitors is not universal in medium and high-risk
syncope patients. In one UK ED study, only 158 of 540 (29%) admitted syncope patients
underwent 24 hour monitoring (which in the majority comprised ward telemetry rather than
Holter). There are other devices available to the Cardiologist to investigate syncope
patients who are classified as European Society of Cardiology (ESC) medium and high-risk and
whose Holter investigation is unrevealing. Event recorders do not record a continuous ECG but
require patient activation at the time of symptoms and must be applied to the chest wall at
the time of the event and must be activated by the patient. A brief, typically 90-second,
single lead ECG recording is captured and stored. Because of limited data storage capability,
data must be transmitted to a monitoring centre for validation and analysis. Event recorders
can be used for cardiac monitoring over longer periods of time but the big drawback is that
they must be activated following symptom onset, which may be difficult to achieve if the
patient has suffered syncope or an injury related to the event. Finally, these devices cannot
be used to document asymptomatic arrhythmias.
External continuous loop recorders are attached to the patient by chest electrodes or a
wristband. They continuously record the ECG but only save data if activated by the patient.
The continuous looping memory feature allows the device to store a fixed length of
pre-activation and post-event ECG data. Mobile cardiac telemetry systems provide up to 30
days of real-time continuous cardiac monitoring without the need for patient activation or
data transmission. These devices are expensive, require electrodes and bulky recording
devices, and produce a large amount of data, which requires sifting. Implantable loop
recorders are surgically implanted subcutaneous devices that continuously record single-lead
ECG signal through 2 electrodes. They are very expensive and necessitate an invasive surgical
procedure. For patients admitted to hospital and who are placed on telemetry, there is also
lack of consensus on the optimal duration of monitoring. Typically higher risk patients are
monitored for 24 hours and discharged without a diagnosis if their ECG tracing has been
uneventful during this time period.
In order to solve these problems, a novel ambulatory cardiac monitoring device that can
easily be applied to ED patients has recently been developed. The ZIO®XT Patch (iRhythm
Technologies, Inc. San Francisco, California; http://www.irhythmtech.com/zio-services.php) is
non-invasive, water-resistant, has no leads or wires, is discrete to wear and has been
approved for clinical use in the UK. It continuously monitors the heart for up to 14 days
including during sleep, in the shower, and during moderate exercise and has a large button on
top for patients to capture symptomatic events. When patients reach the end of their
monitoring period, they simply mail the device back to the company where analysis is
undertaken.
The ZIO®XT Patch is well tolerated for prolonged monitoring and compliance is excellent with
studies demonstrating a mean monitoring wear time of 10.8 days (range 4-14 days) and 10.9
days (median 13.0 days). Barrett et al showed that 80% of patients who had worn a Holter
monitor for 24 hours, and a ZIO®XT Patch for up to 14 days, preferred the ZIO Patch. Single
channel ECG data quality is also excellent with one study showing more than 98% of the total
recording time was analysable, and a second study showing a median analysable time of 99% of
the total wear time. Compliance with returning the device is also good. In a study of 174 ED
with indications for monitoring (syncope, dizziness and palpitations), all patients mailed
back their devices.
Several studies have shown that ZIO®XT Patch has a higher diagnostic yield for arrhythmias
than traditional 24-48 hour Holter monitoring and importantly can also efficiently
characterise symptomatic patients without significant arrhythmia. The absence of an
arrhythmia during syncope, palpitations or a triggered event does not by itself provide a
definitive diagnosis but does allow the clinician to exclude an arrhythmia as a potential
cause and is thus clinically useful. Over half of patients (53.4%) in one study did not have
an arrhythmia despite a triggered event. This allows the clinician to potentially exclude an
arrhythmia as an etiology of the patient's symptoms and potentially avoid further cardiac
evaluation.
Camm et al showed in a study on patients with arrhythmogenic right ventricular dysplasia
(ARVD), that over the total wear time of both devices, the ZIO®XT Patch detected more
premature ventricular contraction events than a 24 hour Holter monitor. Barrett et al showed
ZIO®XT Patch had a 57% greater diagnostic yield than a 24 hour Holter monitor, and Schreiber
at al demonstrated an overall diagnostic yield of 63% in ED patients with indications for
monitoring. This study also showed that 48% of patients had ≥1 arrhythmia and 10% were
symptomatic at the time of their arrhythmia. Median time to first arrhythmia was 1.0 days
(IQR 0.2-2.8) and median time to first symptomatic arrhythmia was 1.5 days (IQR 0.4-6.7). 54%
of symptomatic patients did not have any arrhythmia during their triggered events.
In a study looking at ZIO®XT Patch use in outpatients with clinical indications for
monitoring (15% of whom had syncope), of the 60% of patients who had an arrhythmia detected,
30% had their first arrhythmia and 51% had their first symptom-triggered arrhythmia occur
after the initial 48-hour period. Mean time to first arrhythmia was 1.7 days (median 0.8) and
mean time to first symptomatic arrhythmia was 3.0 days (median 2.1).
This novel ambulatory cardiac monitoring device should allow much earlier arrhythmia
detection in more patients allowing better diagnosis and subsequent treatment.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT06038708 -
Head-up Tilt Test in Patients With Reflex Syncope and Asystolic Response Who Received a Dual-chamber Pacemaker With the Closed Loop Stimulation (CLS) and Participated in the BIOSync Trial
|
||
Completed |
NCT00069693 -
Evaluation of Chronic Orthostatic Intolerance
|
N/A | |
Not yet recruiting |
NCT05649891 -
Checklists Resuscitation Emergency Department
|
N/A | |
Completed |
NCT02565238 -
BIO.MASTER.BioMonitor 2 Study
|
N/A | |
Active, not recruiting |
NCT01965899 -
Usability Study to Assess the Reveal LINQ Insertable Cardiac Monitor System
|
N/A | |
Completed |
NCT00746564 -
Study of New Implantable Loop Recorder
|
N/A | |
Completed |
NCT00359203 -
ISSUE3: International Study on Syncope of Uncertain Etiology 3
|
Phase 4 | |
Recruiting |
NCT04972071 -
SW-RCT Implementation of Canadian Syncope Risk Score Based Practice Recommendations
|
N/A | |
Completed |
NCT04198220 -
BIO|STREAM.ICM Obesity
|
||
Recruiting |
NCT04533425 -
Practical Approaches to Care in Emergency Syncope
|
||
Completed |
NCT05571254 -
The Management of Transient Loss of Consciousness and Suspected Syncope in European Emergency Departments
|
||
Recruiting |
NCT05621460 -
The Effect of Water Carbonation on Orthostatic Tolerance
|
N/A | |
Not yet recruiting |
NCT05957315 -
Mobile Cardiac Outpatient Telemetry for Unexplained Syncope
|
N/A | |
Recruiting |
NCT04615065 -
Acutelines: a Large Data-/Biobank of Acute and Emergency Medicine
|
||
Completed |
NCT05729724 -
Effect of Pharmacological Interventions on Systolic Blood Pressure Drops (SynABPM 2 Proof-of-concept)
|
||
Completed |
NCT05782712 -
Rapid Measurement of Adenosine in Syncope Patients
|
||
Completed |
NCT03786640 -
Abbott Brady 3T MRI PMCF
|
||
Recruiting |
NCT03803969 -
ConfirmRxTM: Posture and Activity
|
N/A | |
Recruiting |
NCT05575934 -
Management of Transitory Loss of Consciousness and Syncopes in the Emergency Department
|
||
Recruiting |
NCT04075084 -
Observation of Clinical Routine Care for Patients With BIOTRONIK Implantable Cardiac Monitors (ICMs)
|